Jacobs, J. W., et al. (2022). Chronic myeloid leukemia with pure erythroid leukemia blast crisis. Leuk Lymphoma, 63(1), 212–216.

Article  CAS  PubMed  Google Scholar 

Zhou, H., & Xu, R. (2015). Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell, 6(6), 403–412.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Minciacchi, V. R., Kumar, R., & Krause, D. S. (2021). Chronic myeloid leukemia: a model disease of the past, present and future. Cells, 10(1), 117.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Breccia, M., et al. (2021). Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA). Ann Hematol, 100(2), 481–485.

Article  CAS  PubMed  Google Scholar 

Mu, H., et al. (2021). Combination therapies in chronic myeloid leukemia for potential treatment-free remission: focus on leukemia stem cells and immune modulation. Front Oncol, 11, 643382.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baessler, A. & Vignali D. A. A. (2024). T Cell Exhaustion. Annu Rev Immunol, 42(1), 179–206 .

Belk, J. A., Daniel, B., & Satpathy, A. T. (2022). Epigenetic regulation of T cell exhaustion. Nat Immunol, 23(6), 848–860.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wik, J. A., & Skålhegg, B. S. (2022). T cell metabolism in infection. Front Immunol, 13, 840610.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yao, D., et al. (2023). Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment. Front Immunol, 14, 1078118.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mumprecht, S., et al. (2010). Chronic myelogenous leukemia maintains specific CD8(+) T cells through IL-7 signaling. Eur J Immunol, 40(10), 2720–2730.

Article  CAS  PubMed  Google Scholar 

Bachireddy, P., et al. (2014). Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood, 123(9), 1412–1421.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang, R., et al. (2021). Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun, 12(1), 832.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brück, O., et al. (2018). Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia, 32(7), 1643–1656.

Article  PubMed  Google Scholar 

Pophali, P., Varela, J. C., & Rosenblatt, J. (2024). Immune checkpoint blockade in hematological malignancies: current state and future potential. Front Oncol, 14, 1323914.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McClanahan, F., et al. (2015). PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood, 126(2), 203–211.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mumprecht, S., et al. (2009). Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood, 114(8), 1528–1536.

Article  CAS  PubMed  Google Scholar 

Yuan, H., et al. (2012). Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood, 119(8), 1904–1914.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sakuishi, K., et al. (2010). Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med, 207(10), 2187–2194.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rezaei, M., et al. (2021). TIM-3 in Leukemia; immune response and beyond. Front Oncol, 11, 753677.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wherry, E. J., & Kurachi, M. (2015). Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol, 15(8), 486–499.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barathan, M., et al. (2017). CD8+ T cells of chronic HCV-infected patients express multiple negative immune checkpoints following stimulation with HCV peptides. Cell Immunol, 313, 1–9.

Article  CAS  PubMed  Google Scholar 

Irani, Y. D., et al. (2023). Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia. Blood Adv, 7(11), 2364–2374.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolchok, J. D., et al. (2013). Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med, 369(2), 122–133.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu, J., et al. (2016). Targeting PD-1 and Tim-3 pathways to reverse CD8 T-cell exhaustion and enhance ex vivo T-cell responses to autologous dendritic/tumor vaccines. J Immunother, 39(4), 171–180.

Article  CAS  PubMed  Google Scholar 

Zhou, Q., et al. (2011). Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood, 117(17), 4501–4510.

Article  CAS  PubMed  PubMed Central  Google Scholar